Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 28 02:12PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-11.23 Insider Own0.07% Shs Outstand23.85M Perf Week9.46%
Market Cap12.56M Forward P/E- EPS next Y-3.98 Insider Trans0.00% Shs Float23.83M Perf Month-3.99%
Income-123.42M PEG- EPS next Q-1.33 Inst Own15.58% Short Float / Ratio0.42% / 0.33 Perf Quarter-44.29%
Sales3.99M P/S3.15 EPS this Y61.77% Inst Trans101.93% Short Interest0.10M Perf Half Y-67.70%
Book/sh6.80 P/B0.08 EPS next Y49.06% ROA-63.37% Target Price8.67 Perf Year-78.70%
Cash/sh0.29 P/C1.82 EPS next 5Y- ROE-69.20% 52W Range0.43 - 9.81 Perf YTD-78.39%
Dividend- P/FCF- EPS past 5Y79.97% ROI-101.54% 52W High-94.63% Beta2.35
Dividend %- Quick Ratio1.02 Sales past 5Y0.00% Gross Margin-49.94% 52W Low22.44% ATR0.04
Employees117 Current Ratio1.77 Sales Q/Q- Oper. Margin-3103.01% RSI (14)52.25 Volatility5.48% 6.26%
OptionableNo Debt/Eq0.01 EPS Q/Q57.74% Profit Margin-3094.01% Rel Volume2.17 Prev Close0.49
ShortableYes LT Debt/Eq0.01 EarningsNov 09 AMC Payout- Avg Volume300.24K Price0.53
Recom1.00 SMA206.91% SMA50-8.68% SMA200-73.37% Volume480,368 Change7.67%
Date Action Analyst Rating Change Price Target Change
Apr-18-22Initiated Noble Capital Markets Outperform
Apr-18-19Upgrade ROTH Capital Neutral → Buy $4
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
Today 07:00AM
Nov-20-23 01:57PM
Nov-15-23 07:00AM
Nov-13-23 07:00AM
04:15PM Loading…
Nov-09-23 04:15PM
Nov-02-23 08:00AM
Oct-31-23 05:00PM
Oct-30-23 07:00AM
Oct-26-23 07:00AM
Oct-25-23 08:45AM
Oct-19-23 07:00AM
Oct-18-23 07:00AM
Oct-16-23 07:00AM
Oct-12-23 07:00AM
07:00AM Loading…
Oct-11-23 07:00AM
Oct-09-23 07:00AM
Oct-04-23 07:00AM
Sep-28-23 09:00PM
Sep-27-23 08:30AM
Sep-26-23 10:18AM
Sep-21-23 07:00AM
Sep-19-23 01:54PM
Sep-18-23 07:00AM
Sep-15-23 09:30AM
Sep-14-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:32AM
07:00AM Loading…
Aug-28-23 01:13PM
Aug-21-23 01:18PM
Aug-17-23 07:00AM
Aug-16-23 07:00AM
Aug-10-23 04:30PM
Aug-07-23 07:00AM
Aug-01-23 04:01PM
Jul-31-23 07:00AM
Jul-27-23 09:31PM
Jul-26-23 04:05PM
Jul-24-23 07:00AM
Jul-17-23 07:00AM
Jul-10-23 07:00AM
Jul-06-23 08:09AM
Jul-03-23 07:00AM
Jun-28-23 03:21PM
Jun-26-23 07:00AM
Jun-21-23 08:25AM
Jun-15-23 07:00AM
Jun-07-23 07:00AM
Jun-05-23 07:00AM
May-31-23 01:24PM
May-30-23 07:00AM
May-25-23 04:05PM
May-24-23 07:00AM
May-23-23 07:00AM
May-22-23 07:00AM
May-18-23 07:00AM
May-17-23 07:00AM
May-09-23 01:00PM
May-08-23 07:00AM
May-04-23 07:00AM
May-01-23 11:35AM
Apr-27-23 08:00AM
Apr-24-23 11:34AM
Apr-19-23 07:00AM
Apr-17-23 07:00AM
Apr-13-23 02:12PM
Apr-06-23 04:15PM
Apr-05-23 07:00AM
Apr-04-23 07:00AM
Mar-30-23 07:00AM
Mar-27-23 07:00AM
Mar-23-23 04:15PM
Mar-22-23 07:00AM
Mar-16-23 04:05PM
Mar-13-23 07:00AM
Mar-07-23 07:00AM
Feb-24-23 11:39AM
Feb-23-23 04:15PM
Feb-22-23 07:00AM
Feb-16-23 07:00AM
Feb-13-23 09:30AM
Feb-10-23 09:30AM
Feb-09-23 07:00AM
Feb-06-23 07:00AM
Feb-03-23 07:00AM
Feb-02-23 01:18PM
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.